# Innovent Biologics

Suzhou-based innovator of domestic PD-1 inhibitors and biosimilars, exporting oncology biologics under accelerated NMPA pathways.


Source: https://cn.bioecon.ru/companies/innovent-biologics/
Updated: 2026-07-29

- 国家: China

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 分别来自与 Takeda 和 Eli Lilly 合作的 US$12 亿和 US$3.5 亿预付款 | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf |
| 产能 | 总运营产能140,000升 | https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=584, https://investor.innoventbio.com/media/1343/innovent-2025-annual-results_for-website.pdf, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| 认证 | 苏州生产基地获EMA药品生产质量管理规范（GMP）证书 | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| 监管批准 | 截至2026年4月，中国获批产品18个 | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf |
| 生产基地 | 苏州（抗体及ADC产能）和杭州（抗体产能） | https://investor.innoventbio.com/media/1343/innovent-2025-annual-results_for-website.pdf, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| 员工人数 | 全球约9,000名员工（截至2026年8月） | https://stockanalysis.com/quote/hkg/1801/employees/, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| 营收 | 2026 年上半年总收入为 86 亿元人民币 | https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |

独立来源: en.innoventbio.com, hkexnews.hk, investor.innoventbio.com, prnewswire.com, stockanalysis.com

## 技术

- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)